# CEACAM21

> Gene · canonical: https://sugi.bio/atlas/gene/CEACAM21/
> Atlas v1.12.2 · generated 2026-10-13T13:32:47+00:00

## Summary

**CEACAM21** (CEA cell adhesion molecule 21, HGNC:28834) is a protein-coding gene on chromosome 19q13.2, encoding **Cell adhesion molecule CEACAM21** (Q3KPI0).

Predicted to be involved in T cell activation and immune response. Predicted to be located in membrane. Predicted to be active in external side of plasma membrane.

*Source: [NCBI Gene 90273](https://www.ncbi.nlm.nih.gov/gene/90273) — automated summary from GO annotations (Alliance of Genome Resources).*

**At a glance**

- **GWAS associations:** 4
- **Clinical variants (ClinVar):** 63 total
- **GTEx eGene:** eQTL in 44 tissues, sQTL in 18 (q < 0.05)
- **Constraint (gnomAD):** pLI 0.00 (LoF-tolerant), LOEUF 1.43 (unconstrained)
- **MANE Select transcript:** `NM_001098506`
- **Notable:** 63 clinical variants but no curated precision-oncology (CIViC) evidence yet




## Identifiers

### Gene identifiers

| Field | Value |
| --- | --- |
| HGNC ID | HGNC:28834 |
| Approved symbol | CEACAM21 |
| Name | CEA cell adhesion molecule 21 |
| Location | 19q13.2 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | R29124_1, FLJ13540 |
| Ensembl gene | ENSG00000007129 |
| Ensembl biotype | protein_coding |
| OMIM | 618191 |
| Entrez | 90273 |

## Gene structure

### Transcript identifiers

**Ensembl transcripts: 16** — 9 protein_coding, 5 nonsense_mediated_decay, 2 protein_coding_CDS_not_defined

**MANE Select:** `ENST00000401445`

**Transcript support level (Ensembl TSL; 1 = fully mRNA-supported):** TSL 1: 3, TSL 2: 1, TSL 3: 1, TSL 5: 2

`ENST00000401445`, `ENST00000187608`, `ENST00000407170`, `ENST00000457737`, `ENST00000482870`, `ENST00000618577`, `ENST00000632983`, `ENST00000890424`, `ENST00000890425`, `ENST00000967641`, `ENST00000996526`, `ENST00000996527`, `ENST00001019376`, `ENST00001019377`, `ENST00001019378`, `ENST00001137688`

**RefSeq mRNA: 4** — MANE Select: `NM_001098506`
`NM_001098506`, `NM_001288773`, `NM_001290113`, `NM_033543`

**CCDS:** `CCDS46086`, `CCDS46087`, `CCDS74373`

#### Canonical transcript exons

`ENST00000401445` — 7 exons

| Exon | Start | End |
| --- | --- | --- |
| ENSE00001476587 | 41584347 | 41584443 |
| ENSE00001813751 | 41586464 | 41586844 |
| ENSE00001821184 | 41576166 | 41576338 |
| ENSE00003506004 | 41579353 | 41579628 |
| ENSE00003558986 | 41585443 | 41585495 |
| ENSE00003587232 | 41577200 | 41577559 |
| ENSE00003603125 | 41585840 | 41585871 |

### Expression profiles

**Bgee:** expression breadth **ubiquitous**, 132 present calls, max score 92.02.

**FANTOM5 (CAGE):** breadth **broad**, TPM avg 7.9132 / max 396.1095, expressed in 580 samples.

**Highest expression (Bgee):** lymph node, granulocyte, blood, bone marrow cell, bone marrow.

#### Genetic regulation across tissues (GTEx eQTL / sQTL)

CEACAM21 is an **eGene** in GTEx v10 — its expression is genetically regulated (eQTL) in **44** tissues and its splicing (sQTL) in **18** (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant's alternative allele.

showing 20 of 62 significant tissue × QTL associations:

| Tissue | QTL | q-value | Slope | Lead variant |
| --- | --- | --- | --- | --- |
| Whole Blood | eqtl | 8.8e-156 | -0.79 | 19:41586462:A:T |
| Cells EBV-transformed lymphocytes | sqtl | 2.4e-112 | +1.41 | 19:41565931:A:G |
| Whole Blood | sqtl | 8.7e-70 | +0.91 | 19:41586462:A:T |
| Lung | eqtl | 6.2e-48 | -0.67 | 19:41586462:A:T |
| Adipose Subcutaneous | eqtl | 5.6e-45 | -0.60 | 19:41588381:A:G |
| Adipose Visceral Omentum | eqtl | 4.3e-43 | -0.70 | 19:41586462:A:T |
| Lung | sqtl | 9.9e-40 | +0.94 | 19:41586462:A:T |
| Spleen | sqtl | 5.0e-33 | +1.29 | 19:41586462:A:T |
| Breast Mammary Tissue | eqtl | 8.0e-28 | -0.59 | 19:41586462:A:T |
| Thyroid | eqtl | 7.4e-27 | -0.44 | 19:41588381:A:G |
| Testis | sqtl | 1.0e-26 | +0.95 | 19:41586462:A:T |
| Spleen | eqtl | 1.3e-20 | -0.60 | 19:41579520:G:A |
| Artery Tibial | eqtl | 3.2e-20 | -0.45 | 19:41586462:A:T |
| Colon Transverse | eqtl | 3.3e-19 | -0.34 | 19:41577830:C:G |
| Artery Aorta | eqtl | 7.5e-19 | -0.42 | 19:41588381:A:G |
| Adrenal Gland | eqtl | 5.3e-18 | -0.68 | 19:41588381:A:G |
| Brain Hypothalamus | eqtl | 5.6e-18 | -0.60 | 19:41586462:A:T |
| Cells EBV-transformed lymphocytes | eqtl | 3.4e-17 | -0.61 | 19:41586462:A:T |
| Adipose Visceral Omentum | sqtl | 5.4e-15 | +0.67 | 19:41586462:A:T |
| Brain Hypothalamus | sqtl | 4.1e-13 | +0.96 | 19:41586462:A:T |

#### FANTOM5 promoters

5 alternative TSS:

| Promoter ID | TPM avg | Samples expressed |
| --- | --- | --- |
| 176040 | 6.8625 | 414 |
| 176044 | 0.7843 | 290 |
| 208829 | 0.1197 | 49 |
| 176042 | 0.1143 | 25 |
| 176043 | 0.0324 | 8 |

#### Top tissues by expression

showing 100 of 135 tissues by Bgee expression score (0-100, higher = more expressed):

| Tissue | Anatomy ID | Expression score | Quality |
| --- | --- | --- | --- |
| lymph node | UBERON:0000029 | 92.02 | gold quality |
| granulocyte | CL:0000094 | 91.88 | gold quality |
| blood | UBERON:0000178 | 90.93 | gold quality |
| bone marrow cell | CL:0002092 | 88.57 | gold quality |
| bone marrow | UBERON:0002371 | 88.50 | gold quality |
| spleen | UBERON:0002106 | 87.14 | gold quality |
| vermiform appendix | UBERON:0001154 | 85.65 | gold quality |
| placenta | UBERON:0001987 | 79.09 | gold quality |
| leukocyte | CL:0000738 | 78.71 | gold quality |
| monocyte | CL:0000576 | 77.66 | gold quality |
| hypothalamus | UBERON:0001898 | 77.44 | gold quality |
| gall bladder | UBERON:0002110 | 76.86 | gold quality |
| right lung | UBERON:0002167 | 76.78 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 75.62 | silver quality |
| small intestine Peyer's patch | UBERON:0003454 | 75.46 | gold quality |
| rectum | UBERON:0001052 | 75.18 | gold quality |
| substantia nigra | UBERON:0002038 | 74.86 | gold quality |
| small intestine | UBERON:0002108 | 74.23 | gold quality |
| upper lobe of left lung | UBERON:0008952 | 73.55 | gold quality |
| duodenum | UBERON:0002114 | 72.53 | gold quality |
| C1 segment of cervical spinal cord | UBERON:0006469 | 72.22 | gold quality |
| lung | UBERON:0002048 | 71.75 | gold quality |
| omental fat pad | UBERON:0010414 | 69.68 | gold quality |
| smooth muscle tissue | UBERON:0001135 | 69.57 | gold quality |
| apex of heart | UBERON:0002098 | 69.38 | gold quality |
| right coronary artery | UBERON:0001625 | 69.23 | gold quality |
| tonsil | UBERON:0002372 | 68.99 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 68.43 | gold quality |
| adipose tissue | UBERON:0001013 | 68.07 | gold quality |
| subcutaneous adipose tissue | UBERON:0002190 | 66.81 | gold quality |
| right adrenal gland | UBERON:0001233 | 65.80 | gold quality |
| intestine | UBERON:0000160 | 65.64 | gold quality |
| transverse colon | UBERON:0001157 | 65.42 | gold quality |
| fallopian tube | UBERON:0003889 | 65.42 | gold quality |
| right adrenal gland cortex | UBERON:0035827 | 65.03 | gold quality |
| urinary bladder | UBERON:0001255 | 64.68 | gold quality |
| left adrenal gland | UBERON:0001234 | 64.61 | gold quality |
| left adrenal gland cortex | UBERON:0035825 | 64.61 | gold quality |
| adrenal gland | UBERON:0002369 | 64.22 | gold quality |
| colonic epithelium | UBERON:0000397 | 63.59 | gold quality |
| left coronary artery | UBERON:0001626 | 63.33 | gold quality |
| thoracic mammary gland | UBERON:0005200 | 63.04 | gold quality |
| colon | UBERON:0001155 | 62.82 | gold quality |
| right lobe of liver | UBERON:0001114 | 62.49 | gold quality |
| thoracic aorta | UBERON:0001515 | 62.31 | gold quality |
| descending thoracic aorta | UBERON:0002345 | 62.25 | gold quality |
| right lobe of thyroid gland | UBERON:0001119 | 62.19 | gold quality |
| ascending aorta | UBERON:0001496 | 62.12 | gold quality |
| body of stomach | UBERON:0001161 | 61.73 | gold quality |
| left uterine tube | UBERON:0001303 | 61.69 | gold quality |
| temporal lobe | UBERON:0001871 | 61.48 | gold quality |
| metanephros cortex | UBERON:0010533 | 61.47 | gold quality |
| amygdala | UBERON:0001876 | 61.45 | gold quality |
| liver | UBERON:0002107 | 61.09 | gold quality |
| endometrium | UBERON:0001295 | 61.02 | gold quality |
| fundus of stomach | UBERON:0001160 | 61.00 | gold quality |
| tibial nerve | UBERON:0001323 | 60.89 | gold quality |
| saliva-secreting gland | UBERON:0001044 | 60.81 | gold quality |
| material anatomical entity | UBERON:0000465 | 60.80 | gold quality |
| multicellular organism | UBERON:0000468 | 60.80 | gold quality |
| anatomical system | UBERON:0000467 | 60.78 | gold quality |
| minor salivary gland | UBERON:0001830 | 60.75 | gold quality |
| myometrium | UBERON:0001296 | 60.17 | gold quality |
| cortex of kidney | UBERON:0001225 | 60.15 | gold quality |
| Ammon's horn | UBERON:0001954 | 60.06 | gold quality |
| stomach | UBERON:0000945 | 59.96 | gold quality |
| thyroid gland | UBERON:0002046 | 59.70 | gold quality |
| heart | UBERON:0000948 | 59.34 | gold quality |
| prostate gland | UBERON:0002367 | 59.24 | gold quality |
| left lobe of thyroid gland | UBERON:0001120 | 59.21 | gold quality |
| esophagus mucosa | UBERON:0002469 | 59.04 | gold quality |
| right atrium auricular region | UBERON:0006631 | 59.02 | gold quality |
| heart left ventricle | UBERON:0002084 | 58.80 | gold quality |
| muscle layer of sigmoid colon | UBERON:0035805 | 58.60 | gold quality |
| ectocervix | UBERON:0012249 | 58.44 | gold quality |
| body of uterus | UBERON:0009853 | 57.77 | gold quality |
| esophagus | UBERON:0001043 | 57.41 | gold quality |
| right ovary | UBERON:0002118 | 57.30 | gold quality |
| uterine cervix | UBERON:0000002 | 56.98 | gold quality |
| endocervix | UBERON:0000458 | 56.91 | gold quality |
| putamen | UBERON:0001874 | 56.66 | gold quality |
| vagina | UBERON:0000996 | 56.61 | gold quality |
| brain | UBERON:0000955 | 55.95 | gold quality |
| lower esophagus | UBERON:0013473 | 55.94 | gold quality |
| lower esophagus muscularis layer | UBERON:0035833 | 55.93 | gold quality |
| caudate nucleus | UBERON:0001873 | 55.71 | gold quality |
| olfactory segment of nasal mucosa | UBERON:0005386 | 55.56 | gold quality |
| right uterine tube | UBERON:0001302 | 55.51 | gold quality |
| nucleus accumbens | UBERON:0001882 | 55.43 | gold quality |
| esophagogastric junction muscularis propria | UBERON:0035841 | 54.87 | gold quality |
| mucosa of stomach | UBERON:0001199 | 54.85 | gold quality |
| anterior cingulate cortex | UBERON:0009835 | 54.81 | gold quality |
| pituitary gland | UBERON:0000007 | 54.79 | gold quality |
| dorsolateral prefrontal cortex | UBERON:0009834 | 54.59 | gold quality |
| tibial artery | UBERON:0007610 | 54.55 | gold quality |
| Brodmann (1909) area 9 | UBERON:0013540 | 54.55 | gold quality |
| popliteal artery | UBERON:0002250 | 54.52 | gold quality |
| adenohypophysis | UBERON:0002196 | 54.35 | gold quality |
| adult mammalian kidney | UBERON:0000082 | 53.69 | gold quality |
| ovary | UBERON:0000992 | 53.13 | gold quality |

#### Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

| Experiment | Marker? | Max mean expression |
| --- | --- | --- |
| [E-HCAD-5](https://www.ebi.ac.uk/gxa/sc/experiments/E-HCAD-5) | yes | 155.99 |
| [E-ANND-3](https://www.ebi.ac.uk/gxa/sc/experiments/E-ANND-3) | no | 1.37 |

#### HPA expression

RNA tissue specificity: **Tissue enhanced**

showing 60 of 62 HPA tissues / cells by nTPM:

| Tissue / cell | Axis | nTPM | Protein (IHC) |
| --- | --- | --- | --- |
| Bone marrow | tissue | 16.5 | medium |
| Hypothalamus | tissue | 7.3 |  |
| Midbrain | tissue | 5.1 |  |
| Substantia nigra | tissue | 5.1 |  |
| Lymph node | tissue | 5.0 |  |
| Spleen | tissue | 4.0 | low |
| Pons | tissue | 3.8 |  |
| Locus coeruleus | tissue | 3.8 |  |
| Lung | tissue | 3.5 | high |
| Seminal vesicle | tissue | 3.4 | medium |
| Medulla oblongata | tissue | 3.2 |  |
| Tonsil | tissue | 3.2 | medium |
| Spinal cord | tissue | 2.7 |  |
| Endometrium 1 | tissue | 2.5 | medium |
| Thalamus | tissue | 2.4 |  |
| Cervix | tissue | 2.1 | medium |
| Cerebral cortex | tissue | 2.0 | high |
| Basal ganglia | tissue | 2.0 | medium |
| Thymus | tissue | 2.0 |  |
| Appendix | tissue | 2.0 | medium |
| Placenta | tissue | 1.4 | high |
| Amygdala | tissue | 1.1 |  |
| Liver | tissue | 1.1 | medium |
| Small intestine | tissue | 1.0 | medium |
| Stomach 1 | tissue | 0.8 | high |
| Cerebellum | tissue | 0.8 | medium |
| Hippocampal formation | tissue | 0.8 |  |
| Urinary bladder | tissue | 0.7 | medium |
| Hippocampus | tissue | 0.7 | medium |
| Testis | tissue | 0.6 | medium |
| Adipose tissue | tissue | 0.6 | not detected |
| Colon | tissue | 0.6 | medium |
| Ovary | tissue | 0.5 | low |
| Rectum | tissue | 0.5 | medium |
| Nucleus accumbens | tissue | 0.5 |  |
| Gallbladder | tissue | 0.5 | medium |
| Duodenum | tissue | 0.5 | medium |
| Adrenal gland | tissue | 0.5 | medium |
| Retrosplenial cortex | tissue | 0.5 |  |
| Pituitary gland | tissue | 0.4 |  |
| Salivary gland | tissue | 0.4 | medium |
| Smooth muscle | tissue | 0.4 | low |
| Putamen | tissue | 0.4 |  |
| Fallopian tube | tissue | 0.4 | medium |
| Heart muscle | tissue | 0.3 | high |
| Vagina | tissue | 0.3 | medium |
| Epididymis | tissue | 0.3 | medium |
| Choroid plexus | tissue | 0.3 |  |
| Thyroid gland | tissue | 0.3 | medium |
| Occipital cortex | tissue | 0.3 |  |
| Breast | tissue | 0.2 | medium |
| Skin 1 | tissue | 0.1 | medium |
| Esophagus | tissue | 0.1 | medium |
| Parathyroid gland | tissue | 0.1 | high |
| Kidney | tissue | 0.1 | medium |
| Prostate | tissue | 0.1 | high |
| Skeletal muscle | tissue | 0.0 | low |
| Pancreas | tissue | 0.0 | medium |
| Nasopharynx | tissue | -1.0 | medium |
| Bronchus | tissue | -1.0 | medium |

**Brain sub-regions (HPA Brain Atlas):** detected in 188; highest nTPM — Ventromedial nucleus (7.3), Paraventricular nucleus (5.3), Ventral tegmental area (4.1), Arcuate nucleus (3.8), Periaquaductal grey, dorsal (3.5).

### Regulation

**Is transcription factor: no**

#### miRNA regulators (miRDB)

Targeting CEACAM21 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

6 miRNAs:

| miRNA | Max score | Avg score | miRNA target_count |
| --- | --- | --- | --- |
| HSA-MIR-4530 | 99.69 | 66.47 | 1509 |
| HSA-MIR-4291 | 99.20 | 68.88 | 2969 |
| HSA-MIR-892C-5P | 99.16 | 70.56 | 2116 |
| HSA-MIR-5100 | 99.11 | 67.52 | 1098 |
| HSA-MIR-599 | 98.32 | 66.99 | 1037 |
| HSA-MIR-592 | 96.59 | 67.59 | 817 |

### Functional genomics

**gnomAD constraint:** pLI 1.63e-14, LOEUF 1.43, missense Z -0.118 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). [gnomAD](https://gnomad.broadinstitute.org/)

**Regional missense constraint (gnomAD RMC):** no regional variation along `ENST00000401445` — one region, missense o/e 1.06.

### Literature-anchored findings (GeneRIF, showing 1)

- This study revealed CEACAM21 as novel schizophrenia candidate genes in the Jewish population (PMID:21682944)

### Cross-species orthologs

**5 orthologs**

| Organism | Symbol | Gene ID |
| --- | --- | --- |
| mus_musculus | Ceacam9 | ENSMUSG00000007209 |
| mus_musculus | Ceacam15 | ENSMUSG00000078795 |
| rattus_norvegicus | Ceacam15 | ENSRNOG00000028617 |
| rattus_norvegicus | Ceacam9 | ENSRNOG00000046915 |
| rattus_norvegicus | Ceacam15l1 | ENSRNOG00000065825 |

**Paralogs (24):** CEACAM7 (ENSG00000007306), CEACAM1 (ENSG00000079385), CEACAM6 (ENSG00000086548), CEACAM4 (ENSG00000105352), CEACAM5 (ENSG00000105388), PSG8 (ENSG00000124467), CEACAM8 (ENSG00000124469), HEPACAM (ENSG00000165478), PSG6 (ENSG00000170848), CEACAM3 (ENSG00000170956), PSG9 (ENSG00000183668), CEACAM19 (ENSG00000186567), HEPACAM2 (ENSG00000188175), PSG5 (ENSG00000204941), CEACAM18 (ENSG00000213822), CEACAM16 (ENSG00000213892), VSTM5 (ENSG00000214376), PSG3 (ENSG00000221826), PSG7 (ENSG00000221878), PSG1 (ENSG00000231924), PSG2 (ENSG00000242221), PSG11 (ENSG00000243130), PSG4 (ENSG00000243137), CEACAM20 (ENSG00000273777)

#### Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara's model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions' gene symbols aren't in biobtree yet, so each row shows the UniProt accession.

| Organism | UniProt | Identity | Method |
| --- | --- | --- | --- |
| Bos taurus | [A4FUY1](https://www.uniprot.org/uniprotkb/A4FUY1/entry) | 87.1% | Diamond |

### Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

| Symbol | Type | Entrez |
| --- | --- | --- |
| [CEACAM4](/atlas/gene/CEACAM4/) | protein-coding | 1089 |
| [LINC01480](/atlas/gene/LINC01480/) | ncRNA | 101927931 |
| [PCAT19](/atlas/gene/PCAT19/) | ncRNA | 100505495 |

<a id="protein-Q3KPI0"></a>

## Protein

### Protein identifiers

**Cell adhesion molecule CEACAM21** — `Q3KPI0` (reviewed: Q3KPI0)

**Alternative names:** Carcinoembryonic antigen-related cell adhesion molecule 21

**All UniProt accessions (3):** `Q3KPI0`, `A0A0B4J1W4`, `A0A0J9YX60`

#### UniProt curated annotations — [full annotation on UniProt →](https://www.uniprot.org/uniprotkb/Q3KPI0/entry)

**Subcellular location.** Membrane.

**Similarity.** Belongs to the immunoglobulin superfamily. CEA family.

#### Isoforms (3)

| UniProt ID | Names | Canonical? |
| --- | --- | --- |
| Q3KPI0-1 | 1 | yes |
| Q3KPI0-2 | 2 |  |
| Q3KPI0-3 | 3 |  |

**RefSeq proteins (4):** `NP_001091976`*, `NP_001275702`, `NP_001277042`, `NP_291021`  (*=MANE)

#### Domains & families (InterPro)

| ID | Name | Type |
| --- | --- | --- |
| IPR003598 | Ig_sub2 | Domain |
| IPR003599 | Ig_sub | Domain |
| IPR007110 | Ig-like_dom | Domain |
| IPR013106 | Ig_V-set | Domain |
| IPR013783 | Ig-like_fold | Homologous_superfamily |
| IPR036179 | Ig-like_dom_sf | Homologous_superfamily |
| IPR050831 | CEA_cell_adhesion | Family |

**Pfam:** `PF07686`, `PF13927`

**UniProt features (13 total):** splice variant 2, sequence variant 2, topological domain 2, signal peptide 1, chain 1, transmembrane region 1, domain 1, region of interest 1, glycosylation site 1, disulfide bond 1

### Structure

#### Predicted structure (AlphaFold)

| Model | pLDDT | Fraction very-high |
| --- | --- | --- |
| AF-Q3KPI0-F1 | 85.54 | 0.72 |

### Human Protein Atlas

**Protein class:** Predicted membrane proteins, UniProt - Evidence at transcript level

**Protein evidence:** Evidence at protein level

**Antibody reliability (HPA):** IH uncertain

### Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. *Source: UniProtKB sequence features.*

#### Disulfide bonds (1)

| Type | Positions |
| --- | --- |
| Disulfide bond | 166–214 |

#### Glycosylation sites (1)

| Type | Positions |
| --- | --- |
| N-linked (glcnac...) asparagine | 111 |

## Function

### Pathways and Gene Ontology

#### Reactome pathways

**0 curated (TAS)** of 0; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

**MSigDB gene sets: 124** (showing top):
`GAUSSMANN_MLL_AF4_FUSION_TARGETS_A_UP`, `GOCC_CELL_SURFACE`, `DARWICHE_SKIN_TUMOR_PROMOTER_UP`, `DARWICHE_SKIN_TUMOR_PROMOTER_DN`, `DARWICHE_PAPILLOMA_RISK_LOW_UP`, `DARWICHE_PAPILLOMA_RISK_HIGH_UP`, `DARWICHE_SQUAMOUS_CELL_CARCINOMA_UP`, `BROWN_MYELOID_CELL_DEVELOPMENT_UP`, `AFFAR_YY1_TARGETS_UP`, `DOUGLAS_BMI1_TARGETS_UP`, `IVANOVA_HEMATOPOIESIS_STEM_CELL_LONG_TERM`, `GOCC_SIDE_OF_MEMBRANE`, `MATSUDA_NATURAL_KILLER_DIFFERENTIATION`, `YOSHIMURA_MAPK8_TARGETS_UP`, `MIKKELSEN_ES_ICP_WITH_H3K4ME3`

**GO Biological Process (2):**
immune response (GO:0006955), T cell activation (GO:0042110)

**GO Cellular Component (2):**
external side of plasma membrane (GO:0009897), membrane (GO:0016020)

#### GO top-level categories

7 GO namespaces:

| Category | Terms |
| --- | --- |
| immune system process | 1 |
| response to stimulus | 1 |
| lymphocyte activation | 1 |
| plasma membrane | 1 |
| cell surface | 1 |
| side of membrane | 1 |
| cellular anatomical structure | 1 |

### Protein interactions and networks

#### STRING

showing 15 of 472 interactions by confidence (×1000):

| Protein A | Protein B | Partner UniProt | Score |
| --- | --- | --- | --- |
| CEACAM21 | CEACAM19 | Q7Z692 | 603 |
| CEACAM21 | SIGLEC5 | O15389 | 356 |
| CEACAM21 | HOXA2 | O43364 | 348 |
| CEACAM21 | DMAC2 | Q9NW81 | 343 |
| CEACAM21 | EFHB | Q8N7U6 | 306 |
| CEACAM21 | CEACAM18 | A8MTB9 | 271 |
| CEACAM21 | CAPSL | Q8WWF8 | 270 |
| CEACAM21 | CEACAM20 | Q6UY09 | 262 |
| CEACAM21 | FPR1 | P21462 | 261 |
| CEACAM21 | CD177 | Q8N6Q3 | 257 |
| CEACAM21 | S100A12 | P80511 | 255 |
| CEACAM21 | CLEC7A | Q9BXN2 | 245 |
| CEACAM21 | CSF3R | Q99062 | 245 |
| CEACAM21 | C11orf42 | Q8N5U0 | 236 |
| CEACAM21 | Q3SX90 | Q3SX90 | 225 |

#### IntAct

Human interaction partners of CEACAM21 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

5 partners by confidence:

| Partner | Interaction type | MIscore | Records |
| --- | --- | --- | --- |
| LILRA6 | physical association | 0.400 | 1 |
| LILRB1 | physical association | 0.400 | 1 |
| GAPDHS | association | 0.350 | 1 |
| MET | association | 0.350 | 1 |
| VGLL4 | association | 0.350 | 1 |

**BioGRID (149 interactions; top human partners by supporting records):** ABCB10 (Affinity Capture-MS; 3 records), ABHD14A (Affinity Capture-MS; 3 records), ATR (Affinity Capture-MS; 3 records), CCDC51 (Affinity Capture-MS; 3 records), CDON (Affinity Capture-MS; 3 records), CNTN1 (Affinity Capture-MS; 3 records), DAG1 (Affinity Capture-MS; 3 records), EFNB1 (Affinity Capture-MS; 3 records), EPHA4 (Affinity Capture-MS; 3 records), FAT4 (Affinity Capture-MS; 3 records), FUT8 (Affinity Capture-MS; 3 records), GOLGA5 (Affinity Capture-MS; 3 records), ITFG1 (Affinity Capture-MS; 3 records), ITIH2 (Affinity Capture-MS; 3 records), KIAA1524 (Affinity Capture-MS; 3 records)

## Disease & clinical

### Genetic variants

**Variant evidence for CEACAM21:** [63 ClinVar records](#clinvar) (0 pathogenic / likely pathogenic); [4 GWAS associations](#gwas-assoc).

#### ClinVar

63 variants total. Per-class counts are floors (≥ shown; pagination cap):

| Classification | Count (floor) |
| --- | --- |
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 51 |
| Likely benign | 2 |
| Benign | 0 |

#### SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 42 predictions of 644):

| Position(s) | Effect | Δscore | Sites |
| --- | --- | --- | --- |
| 19:41579630 | donor_loss | 1.0000 | 2 |
| 19:41576339–41576340 | donor_loss | 0.9900 | 4 |
| 19:41577560–41577561 | donor_loss | 0.9900 | 5 |
| 19:41579629 | donor_loss | 0.9900 |  |
| 19:41584444–41584445 | donor_loss | 0.9900 | 6 |
| 19:41585441–41585442 | acceptor_loss | 0.9900 | 4 |
| 19:41585496–41585497 | donor_loss | 0.9900 | 5 |
| 19:41585838–41585839 | acceptor_loss | 0.9900 | 6 |
| 19:41585872–41585873 | donor_loss | 0.9900 | 5 |
| 19:41586462–41586463 | acceptor_loss | 0.9900 | 4 |

#### AlphaMissense

288 missense substitutions predicted likely pathogenic (of 1,899 scored), across 102 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

| Residue | Likely-pathogenic substitutions | Mean am_pathogenicity | Max am_pathogenicity |
| --- | --- | --- | --- |
| D116 | 8 | 0.899 | 0.954 |
| D208 | 8 | 0.862 | 0.934 |
| W177 | 7 | 0.950 | 0.992 |
| W67 | 7 | 0.943 | 0.987 |
| C166 | 7 | 0.927 | 0.968 |
| C214 | 7 | 0.922 | 0.981 |
| E99 | 7 | 0.766 | 0.938 |
| S225 | 6 | 0.913 | 0.972 |
| G92 | 6 | 0.896 | 0.939 |
| G210 | 6 | 0.819 | 0.929 |
| G70 | 6 | 0.815 | 0.906 |
| P147 | 6 | 0.804 | 0.943 |
| Y212 | 5 | 0.972 | 0.982 |
| Y120 | 5 | 0.901 | 0.956 |
| G118 | 5 | 0.821 | 0.909 |
| K69 | 5 | 0.796 | 0.914 |
| F179 | 5 | 0.790 | 0.858 |
| V140 | 5 | 0.786 | 0.892 |
| F109 | 5 | 0.768 | 0.936 |
| N218 | 5 | 0.765 | 0.902 |

### HPA cancer prognostics

**RNA cancer specificity:** Cancer enhanced (Uterine Corpus Endometrial Carcinoma)

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

2 prognostic cancer types:

| Cancer | Prognostic | p-value |
| --- | --- | --- |
| Lung Adenocarcinoma (TCGA) | favorable | 0.000829 |
| Kidney Renal Clear Cell Carcinoma (TCGA) | unfavorable | 0.000985 |

### Disease associations

**OMIM:** gene `MIM:618191` | disease phenotypes: 

#### GWAS associations

4 associations:

| Study | Trait | p-value |
| --- | --- | --- |
| GCST001714_2 | Prostate cancer | 2e-12 |
| GCST001714_1 | Prostate cancer | 1e-8 |
| GCST001119_2 | Schizophrenia | 1e-7 |
| GCST004744_57 | Lung adenocarcinoma | 3e-7 |

## Drugs & pharmacology

### Drug and pharmacology data

**Is drug target: no**

**PharmGKB:** 1 entry (CPIC guideline: no)

#### CTD chemical–gene interactions

12 total (human), top 12 by PubMed support.

| Chemical | Actions (top 5) | PubMed papers |
| --- | --- | --- |
| GSK-J4 | decreases expression | 1 |
| triphenyl phosphate | affects expression | 1 |
| pirinixic acid | affects binding, decreases expression, increases activity | 1 |
| arsenite | affects expression | 1 |
| perfluorooctanoic acid | increases expression | 1 |
| S-(1,2-dichlorovinyl)cysteine | affects response to substance, increases expression | 1 |
| di-n-butylphosphoric acid | affects expression | 1 |
| CGP 52608 | affects binding, increases reaction | 1 |
| Amphotericin B | increases expression | 1 |
| Benzo(a)pyrene | affects methylation | 1 |
| Lipopolysaccharides | decreases expression, affects response to substance, increases expression | 1 |
| Antirheumatic Agents | decreases expression | 1 |

#### Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

## Related Atlas pages

*No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.*